

Results of Meeting

Melbourne, Australia, 14 November 2019: [Sienna Cancer Diagnostics Ltd \(ASX: SDX\)](#) (“Sienna” or “the Company”), advises the results of the resolutions of the 2019 Annual General Meeting (AGM). As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda:

Resolution	For	%	Against	%	Abstain	Resolution Result
1 Adoption of Remuneration Report	119,024,745	99.63	447,998	0.37	1,935,046	Carried
2 Resolution Withdrawn						
3 Amendments to the Company Constitution	121,480,328		297,200		1,126,032	Carried
4 Approval of Increased Placement Capacity	121,480,328		297,200		1,126,032	Carried

Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item.

ENDS

For further information, please contact:

Geoff Cumming, Chairman
Sienna Cancer Diagnostics
gcumming@siennadiagnostics.com.au
+61 3 8288 2141

Tony Di Pietro, CFO & Company Secretary
Sienna Cancer Diagnostics
tdipietro@siennadiagnostics.com.au
+61 3 8288 2141

About Sienna Cancer Diagnostics

Sienna Cancer Diagnostics Ltd. (“the Company”, or “Sienna”) is an Australian medical technology company with operations in the United States and Australia, and distributors for its products in the United States, Europe, Asia and Latin America.

Sienna’s vision is to become a hub for the development and commercialisation of *in-vitro* diagnostic (IVD) tests for the global pathology market. Our mission is to create a portfolio of products to bring to market much needed cancer diagnostic solutions, which will in turn generate additional revenue and long-term growth for Sienna’s shareholders.

Sienna’s strengths lie in the identification, development and commercialisation of novel IVD technologies that satisfy an unmet clinical / market need. Our first product is an antibody-based IVD test to detect the biomarker “hTERT”. Sienna has taken the hTERT test from research, through development and manufacturing, to product registration and sales through a growing network of distribution partners.

The Company intends to fill an important gap in the Australian MedTech ecosystem, by providing a capable, efficient and effective development, manufacturing and commercial launch pathway for IVD technologies sourced from leading universities and research institutions.

As part of this technology expansion strategy, Sienna recently acquired a unique technology for the capture and isolation of target biomarkers in liquid biopsy samples. The sample preparation technology, known as SIEN-NET™, can more accurately and rapidly prepare samples for the liquid biopsy testing of a range of clinically useful biomarkers, including exosomes, lipids, proteins, and other molecular targets of interest.





We are focussed on growing revenues from the hTERT test, increasing market access through new distribution partnerships, commercialisation of the SIEN-NET™ product line, and expanding our product offerings with the addition of new technologies.

